Aktie A3DXL9 ELOXX PHARMACEUTICALS, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Eloxx Pharmaceuticals, Inc.

Aktien

A3DXL9

US29014R2022

ELOX

Verzögert OTC Markets
Andere Börsenplätze
 15:38:38 03.05.2024 		% 5 Tage % 1. Jan.
0.895 USD +5.29% Intraday Chart für Eloxx Pharmaceuticals, Inc. +8.48% -25.42%
13.03. Almirall und Eloxx Pharmaceuticals schließen Exklusivvertrag zur Lizenzierung von ZKN-013 für seltene dermatologische Erkrankungen ab CI
13.03. Almirall unterzeichnet Lizenzvertrag mit Eloxx Pharmaceuticals zur Behandlung von Hautkrankheiten MT

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates
North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases
Eloxx Pharmaceuticals : Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases
Almirall Signs License Deal with Eloxx Pharmaceuticals for Skin Diseases Treatment
Eloxx Pharmaceuticals, Inc. Enters into the Fifth Amendment to the Loan and Security Agreement
Eloxx Pharmaceuticals, Inc. Announces Resignation of Tomer Kariv from the Board
Eloxx Pharmaceuticals, Inc. and Zikani Therapeutics, Inc. Enter into the Fourth Amendment to the Loan and Security Agreement
Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update
Eloxx Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Eloxx Pharmaceuticals, Inc.(NasdaqCM:ELOX) dropped from S&P TMI Index
Eloxx Pharmaceuticals, Inc.(OTCPK:ELOX) dropped from NASDAQ Composite Index
Eloxx Pharmaceuticals : October 2023 Investor Presentation
Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction
Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria
Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome
Eloxx Pharmaceuticals, Inc. Announces Resignation of Vijay Modur as Head of Research and Development
Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013
Eloxx Pharmaceuticals, Inc. Provides Updates on ELX-02 and ZKN-013
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3DXL9 Aktie
  4. Nachrichten Eloxx Pharmaceuticals, Inc.
  5. Andere Sprachen